加载中
NASDAQBasic MaterialsAgricultural Inputs
最新数据
US$0.8575
−US$0.0263 · -2.98%
Nexentis Technologies Inc., through its subsidiary, develops therapeutics related to cancer and inflammatory metabolic diseases. It operates through two segments, Biotechnology Activity and Renewable Energy Projects. The company's pipeline includes MITOLINE, an algorithm used to perform multiple sequence/ structure pairwise alignments which could then be used for generating a 3D comparative model of potentially all mitochondrial carrier proteins; cloud-based computational chemistry platform; and novel in-vitro screening platforms; and advanced 3D NSCLC tumor spheroid systems.The company was formerly known as N2OFF, Inc. and changed its name to Nexentis Technologies Inc. in February 2026. Nexentis Technologies Inc. was incorporated in 2009 and is headquartered in Ness Ziona, Israel.
前收盘价
US$0.8575
−US$0.0263 · -2.98%
盘中时间采用ET。市场数据可能有所延迟。
Nexentis Technologies Inc., through its subsidiary, develops therapeutics related to cancer and inflammatory metabolic diseases. It operates through two segments, Biotechnology Activity and Renewable Energy Projects. The company's pipeline includes MITOLINE, an algorithm used to perform multiple sequence/ structure pairwise alignments which could then be used for generating a 3D comparative model of potentially all mitochondrial carrier proteins; cloud-based computational chemistry platform; and novel in-vitro screening platforms; and advanced 3D NSCLC tumor spheroid systems.The company was formerly known as N2OFF, Inc. and changed its name to Nexentis Technologies Inc. in February 2026. Nexentis Technologies Inc. was incorporated in 2009 and is headquartered in Ness Ziona, Israel.
日内区间
当前US$0.8575
52周区间
当前US$0.8575
盘中时间采用ET。市场数据可能有所延迟。
Nexentis Technologies Inc., through its subsidiary, develops therapeutics related to cancer and inflammatory metabolic diseases. It operates through two segments, Biotechnology Activity and Renewable Energy Projects. The company's pipeline includes MITOLINE, an algorithm used to perform multiple sequence/ structure pairwise alignments which could then be used for generating a 3D comparative model of potentially all mitochondrial carrier proteins; cloud-based computational chemistry platform; and novel in-vitro screening platforms; and advanced 3D NSCLC tumor spheroid systems.The company was formerly known as N2OFF, Inc. and changed its name to Nexentis Technologies Inc. in February 2026. Nexentis Technologies Inc. was incorporated in 2009 and is headquartered in Ness Ziona, Israel.
日内区间
当前US$0.8575
52周区间
当前US$0.8575
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | — | 21万 USD | 26.34万 USD | 39.4万 USD | 43.81万 USD |
| 销货成本 | — | 17.7万 USD | 7.63万 USD | 18.85万 USD | 19.41万 USD |
| 毛利 | — | 3.3万 USD | 18.71万 USD | 20.55万 USD | 24.4万 USD |
| 研究与开发 | 17.9万 USD | 36.7万 USD | 192.53万 USD | 74.88万 USD | 50.05万 USD |
| 销售、一般及管理费用 | 510.9万 USD | 371.5万 USD | 556.33万 USD | 516.76万 USD | 428.63万 USD |
| 营业费用 | 423万 USD | 408.2万 USD | 748.86万 USD | 591.64万 USD | 478.68万 USD |
| 利息收入 | — | 6.5万 USD | 6.58万 USD | — | — |
| 利息支出 | 11.4万 USD | 9.5万 USD | 5358 USD | 8797 USD | 4.46万 USD |
| 折旧和摊销 | 7.1万 USD | 1.8万 USD | 2.12万 USD | 5.47万 USD | 5.82万 USD |
| 营业利润 | −423万 USD | −404.9万 USD | −730.14万 USD | −571.08万 USD | −454.28万 USD |
| 净利润 | −400.4万 USD | −519.3万 USD | −652.24万 USD | −573.96万 USD | −482.06万 USD |
公司数据更新于 2026年10月11日。
近期已公布业绩
近期已公布业绩
| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2026年4月7日 | 1:7 | — | — |
股票拆分 | 2025年9月22日 | 1:35 | — | — |
股票拆分 | 2023年10月6日 | 1:7 | — | — |
股票拆分 | 2021年2月25日 | 1:7 | — | — |
股票拆分 | 2019年6月13日 | 1:15 | — | — |
已生效 2026年4月7日
1:7
已生效 2025年9月22日
1:35
已生效 2023年10月6日
1:7
已生效 2021年2月25日
1:7
已生效 2019年6月13日
1:15
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
